Article
α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.
Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 Jun 2024
Levin Johannes, Baiardi Simone, Quadalti Corinne, Rossi Marcello, Mammana Angela, Vöglein Jonathan, Bernhardt Alexander, Perrin Richard J, Jucker Mathias, Preische Oliver, Hofmann Anna, Höglinger Günter U, Cairns Nigel J, Franklin Erin E, Chrem Patricio, Cruchaga Carlos, Berman Sarah B, Chhatwal Jasmeer P, Daniels Alisha, Day Gregory S, Ryan Natalie S, Goate Alison M, Gordon Brian A, Huey Edward D, Ibanez Laura, Karch Celeste M, Lee Jae-Hong, Llibre-Guerra Jorge, Lopera Francisco, Masters Colin L, Morris John C, Noble James M, Renton Alan E, Roh Jee Hoon, Frosch Matthew P, Keene C Dirk, McLean Catriona, Sanchez-Valle Raquel, Schofield Peter R, Supnet-Bell Charlene, Xiong Chengjie, Giese Armin, Hansson Oskar, Bateman Randall J, McDade Eric, Parchi Piero
Abstract excerpt
INTRODUCTION: Amyloid beta and tau pathology are the hallmarks of sporadic Alzheimer's disease (AD) and autosomal dominant AD (ADAD). However, Lewy body pathology (LBP) is found in ≈ 50% of AD and ADAD brains. METHODS: Using an α-synuclein seed amplification assay (SAA) in cerebrospinal fluid (CSF) from asymptomatic (n = 26) and symptomatic (n = 27) ADAD mutation carriers, including 12 with known neuropathology,...
Read the complete abstract on PubMed